CH, an age-related expansion of mutated blood cells, is an established marker for immune dysregulation, increased inflammatory disease, and hematologic cancer risk.24, 25, 26, 27 A landmark study of 17 182 individuals without prevalent hematologic cancers found that somatic CHIP mutations increase the risk of developing hematologic malignancies by 11-fold and to increase all-cause mortality by 1.4-fold, largely driven by cardiovascular causes.5 Here, STUB1 is linked to hematologic disorder.